FrancophonIA/ELRC3.0 huggingface dataset:
English: Copalia HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide.
Estonian: Copalia HCT-d kasutatakse essentsiaalse hüpertensiooniga (kõrgvererõhutõvega) täiskasvanutel, kelle vererõhk allub piisavalt ravile amlodipiini, valsartaani ja hüdroklorotiasiidi kombinatsiooniga.
English: Other information about Copalia HCT
Estonian: Muu teave Copalia HCT kohta
English: The dose of Copalia HCT to be used is the same as the doses of three individual active substances that the patient was taking before.
Estonian: Copalia HCT-d tuleb anda samas annuses kui kolme toimeainet, mida patsient varem eraldi võttis.
English: Treatment with the highest strength of Copalia HCT was more effective at treating hypertension than dual combinations containing any of the two active substances.
Estonian: Ravi Copalia HCT suurima annusega oli vererõhu alandamisel efektiivsem kui ravi mis tahes kahe toimeaine kombinatsiooniga.
English: For the full list of all side effects reported with Copalia HCT, see the package leaflet.
Estonian: Copalia HCT kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Copalia HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Copalia HCT.
Estonian: Copalia HCT-d ei tohi kasutada patsiendid, kes on selle toimeainete, teiste sulfoonamiidide, dihüdropüridiini derivaatide klassi kuuluvate toimeainete või Copalia HCT mis tahes muude koostisainete suhtes ülitundlikud (allergilised).
English: The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Copalia HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively.
Estonian: Copalia HCT-d manustanud patsientidel alanes vererõhk keskmiselt 39,7/24,7 mmHg võrra, ent valsartaani-hüdroklorotiasiidi, valsartaani-amlodipiini või hüdroklorotiasiidi-amlodipiini kombinatsiooni manustanud patsientidel vastavalt 32/19,7 mmHg, 33,5/21,5 mmHg ja 31,5/19,5 mmHg võrra.
English: Patients received either Copalia HCT or one of the three combinations containing only two of the active substances for eight weeks.
Estonian: Patsiendid manustasid kaheksa nädala jooksul kas Copalia HCT-d või kahe toimeaine kolmest kombinatsioonist ühte kombinatsiooni.
English: What is Copalia HCT?
Estonian: Mis on Copalia HCT?
English: What is the risk associated with Copalia HCT?
Estonian: Mis riskid Copalia HCT-ga kaasnevad?
English: Why has Copalia HCT been approved?
Estonian: Miks Copalia HCT heaks kiideti?
English: For all doses, Copalia HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken separately.
Estonian: Copalia HCT kõigi annuste kohta tõendati, et nende mõju on sama mis kolmel toimeainel eraldi võetuna.
English: How does Copalia HCT work?
Estonian: Kuidas Copalia HCT toimib?
English: Finally, Copalia HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.
Estonian: Copalia HCT-d ei tohi anda ka patsientidele, kellel on ravile allumatu hüpokaleemia (vere kaaliumivaegus), hüponatreemia (vere naatriumivaegus) või hüperkaltseemia
English: What benefit has Copalia HCT shown during the studies?
Estonian: Milles seisneb uuringute põhjal Copalia HCT kasulikkus?
English: How has Copalia HCT been studied?
Estonian: Kuidas Copalia HCT-d uuriti?
English: Copalia HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Estonian: II tüüpi diabeediga või mõõduka või raske neerupuudulikkusega patsiendid ei tohi kasutada Copalia HCT-d koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
English: How is Copalia HCT used?
Estonian: Kuidas Copalia HCT-d kasutatakse?
English: What is Copalia HCT used for?
Estonian: Milleks Copalia HCT-d kasutatakse?
English: Hydrochlorothiazide is a diuretic.
Estonian: Copalia HCT on retseptiravim.
English: The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
Estonian: Kehtivad ravimi omaduste kokkuvõte, märgistus ja pakendi infoleht on Koordineerimisrühma menetluse tulemusena saavutatud lõplikud versioonid.
English: SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
Estonian: RAVIMI OMADUSTE KOKKUVÕTE,PAKENDI MÄRGISTUS JA INFOLEHT
English: 1 1 dose (0.5 ml) contains approximately:
Estonian: 1 1 annus (0,5 ml) sisaldab umbes:
English: b L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology c adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al)
Estonian: b L1-valgud viiruste moodi osakestena, mis on toodetud pärmirakkudes (Saccharomyces cerevisiae CANADE 3C-5 (tüvi 1895)) kasutades rekombinantset DNA tehnoloogiat c adsorbeerituna vaktsiinide abiainele amorfsele alumiiniumhüdroksüfosfaatsulfaadile (225 mikrogrammi alumiiniumi).
English: Human Papillomavirusa Type 11 L1 proteinb,c 40 micrograms Human Papillomavirusa Type 16 L1 proteinb,c 40 micrograms Human Papillomavirusa Type 18 L1 proteinb,c 20 micrograms a Human Papillomavirus = HPV
Estonian: inimese papilloomiviirusea tüübi 6 L1-proteiini b,c inimese papilloomiviirusea tüübi 18 L1-proteiinib,c a Inimese papilloomiviirus, Human Papillomavirus, HPV.
English: These three-week cycles should be repeated until the disease gets worse or side effects become unacceptable.
Estonian: Selliseid kolmenädalaseid tsükleid tuleb korrata seni, kuni haigus hakkab süvenema või kui kõrvalnähud muutuvad vastuvõetamatuteks.
English: What measures are being taken to ensure the safe and effective use of Lartruvo?
Estonian: Mis meetmed võetakse, et tagada Lartruvo ohutu ja efektiivne kasutamine?
English: This protein is often found on the surface of cells where it plays a role in regulating cell multiplication.
Estonian: Seda valku esineb sageli rakupinnal, kus ta osaleb rakkude paljunemise reguleerimises.
English: Lartruvo olaratumab
Estonian: Lartruvo olaratumaab
English: Doxorubicin is given on day 1 of each cycle, after the Lartruvo infusion.
Estonian: Doksorubitsiini manustatakse iga tsükli 1. päeval pärast Lartruvo infusiooni.
English: Other information about Lartruvo
Estonian: Muu teave Lartruvo kohta
English: The most serious side effects were neutropenia and musculoskeletal pain.
Estonian: Kõige raskemad kõrvalnähud olid neutropeenia ja lihase-skeleti valu.
English: What is Lartruvo and what is it used for?
Estonian: Mis on Lartruvo ja milleks seda kasutatakse?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Lartruvo's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Lartruvo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: This is a summary of the European public assessment report (EPAR) for Lartruvo.
Estonian: See on ravimi Lartruvo Euroopa avaliku hindamisaruande kokkuvõte.
English: However, because of the small number of patients included in the main study, further data will be needed from the company that markets the medicine.
Estonian: Põhiuuringus osalenud patsientide väikese arvu tõttu peab ravimit turustav ettevõte esitama lisaandmeid.
English: Since Lartruvo has been granted a conditional approval, the company that markets Lartruvo will provide additional data from an ongoing study in order to further confirm the efficacy and safety of the medicine.
Estonian: Et Lartruvo on saanud müügiloa tingimusliku heakskiidu alusel, esitab Lartruvot turustav ettevõte toimuva uuringu lisaandmed, et veelgi kinnitada ravimi efektiivsust ja ohutust.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Lartruvo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Lartruvo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The recommended dose of Lartruvo is 15 mg per kilogram body weight, given twice over a period of three weeks, on days 1 and 8.
Estonian: Lartruvo soovitatav annus on 15 mg kehamassi kg kohta manustatuna kaks korda kolmenädalase perioodi jooksul 1. ja 8. päeval.
English: During the infusion, patients should be monitored for signs and symptoms of infusion-related reactions and trained staff and equipment for emergency resuscitation should be available.
Estonian: Infusiooni ajal peab jälgima patsientide infusiooniga seotud reaktsioonide tunnuseid ja sümptomeid ning on vajalik kogenud personali ja elustamisvahendite kättesaadavus.
English: The full EPAR for Lartruvo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Lartruvo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Because the number of patients with soft tissue sarcoma is low, the disease is considered ‘rare', and Lartruvo was designated an ‘orphan medicine' (a medicine used in rare diseases) on 12 February 2015.
Estonian: Et pehmekudede sarkoomiga patsientide arv on väike ja see haigus esineb harva, nimetati Lartruvo 12. veebruaril 2015 harvikravimiks (harvaesinevate haiguste korral kasutatav ravim).
English: It is not intended to provide practical advice on how to use Lartruvo.
Estonian: Hindamisaruandes ei anta Lartruvo kasutamise praktilisi nõuandeid.
English: Why is Lartruvo approved?
Estonian: Miks Lartruvo heaks kiideti?
English: What information is still awaited for Lartruvo?
Estonian: Mis teavet Lartruvo kohta veel oodatakse?
English: The most frequent side effects which lead to treatment termination were infusion-related reactions (allergic reactions which can be serious, with symptoms such as chills, fever and difficulty breathing) and mucositis.
Estonian: Kõige sagedamad ravi lõpetamist põhjustavad kõrvalnähud olid infusiooniga seotud reaktsioonid (allergilised reaktsioonid, mis võivad olla rasked ja millega kaasnevad sellised sümptomid nagu külmavärinad, palavik ja hingamisraskus) ja mukosiit.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lartruvo have been included in the summary of product characteristics and the package leaflet.
Estonian: Lartruvo ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: What are the risks associated with Lartruvo?
Estonian: Mis riskid Lartruvoga kaasnevad?
English: With regards to the safety profile of the medicine, it was observed that patients treated with Lartruvo plus doxorubicin experienced an increase in the frequency of side effects; however, in view of the benefits of treatment, side effects were considered tolerable and manageable.
Estonian: Ravimi ohutusprofiili seisukohalt täheldati, et Lartruvo ja doksorubitsiini kombinatsiooniga ravitud patsientidel esines kõrvalnähte sagedamini, kuid arvestades ravist saadavat kasu peeti kõrvalnähte talutavateks ja ohjatavateks.
English: Lartruvo has been given ‘conditional approval'.
Estonian: Lartruvo müügiluba anti tingimuslikult.
English: By attaching to PDGFRα on sarcoma cells, Lartruvo is expected to block its activity, thereby slowing down the growth of the cancer.
Estonian: Sarkoomirakkude PDGFRα külge kinnitudes blokeerib Lartruvo eeldatavalt selle valgu toime, aeglustades seega pahaloomulise kasvaja kasvu.
English: In addition, patients treated with the combination Lartruvo plus doxorubicin lived overall almost twice as long as patients treated with doxorubicin (26.5 versus 14.7 months, respectively).
Estonian: Lisaks elasid Lartruvo ja doksorubitsiini kombinatsiooni kasutanud patsiendid kokkuvõttes ligikaudu kaks korda kauem kui ainult doksorubitsiini kasutanud patsiendid (vastavalt 26,5 kuud ja 14,7 kuud).
English: Lartruvo is given in combination with doxorubicin for up to 8 cycles of treatment, followed by Lartruvo alone in patients whose disease has not got worse.
Estonian: Lartruvot manustatakse kombinatsioonis doksorubitsiiniga kuni 8 ravikuuri, misjärel jätkatakse patsientidel, kelle haigus ei ole süvenenud, ravi ainult Lartruvoga.
English: For the full list of all side effects and restrictions with Lartruvo, see the package leaflet.
Estonian: Lartruvo kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: In cancers such as soft tissue sarcoma, this protein is present in high levels or is overactive, causing cells to become cancerous.
Estonian: Vähkides nagu pehmekudede sarkoom on seda valku väga palju või on see üliaktiivne, põhjustades rakkude muutumise pahaloomulisteks.
English: Lartruvo can only be obtained with a prescription and treatment must be started and monitored by a doctor experienced in the treatment of cancer.
Estonian: Ravi tohib alustada ning jälgida ainult vähiravimite kasutamises kogenud arst.
English: The study showed that Lartruvo plus doxorubicin was more effective than doxorubicin alone at prolonging the time patients live without their disease getting worse (progression-free survival).
Estonian: Uuring tõestas, et Lartruvo ja doksorubitsiini kombinatsioon oli ainuravimist doksorubitsiinist efektiivsem selle aja pikendamisel, mil patsiendid elasid haiguse süvenemiseta (progressioonivaba elumus).
English: For more information about treatment with Lartruvo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Lartruvoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Lartruvo has been investigated in one main study involving 133 adults with advanced soft tissue sarcoma who couldn't undergo surgery or radiotherapy and who had not been previously treated with anthracyclines (a group of cancer medicines that includes doxorubicin).
Estonian: Lartruvot on uuritud ühes põhiuuringus, kus osales 133 pehmekudede kaugelearenenud sarkoomiga patsienti, keda ei olnud võimalik opereerida ega ravida kiiritusraviga ja keda varem ei olnud ravitud antratsükliinidega (vähiravimite rühm, kuhu kuulub ka doksorubitsiin).
English: For practical information about using Lartruvo, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Lartruvo kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Data from the main study show that Lartruvo in combination with doxorubicin improves progressionfree and overall survival of patients with advanced soft tissue sarcoma.
Estonian: Põhiuuringu andmed tõendavad, et Lartruvo ja doksorubitsiini kombinatsioon parandab pehmekudede kaugelearenenud sarkoomiga patsientide progressioonivaba elumust ja üldist elumust.
English: Patients treated with Lartruvo plus doxorubicin lived for an average of 6.6 months without their disease getting worse, compared with 4.1 months for patients treated with doxorubicin alone.
Estonian: Lartruvo ja doksorubitsiini kombinatsiooni kasutanud patsientide haigus ei süvenenud keskmiselt 6,6 kuud, samas kui ainult doksorubitsiini kasutanud patsientide vastav näitaja oli 4,1 kuud.
English: How does Lartruvo work?
Estonian: Kuidas Lartruvo toimib?
English: The most common side effects with Lartruvo (which may affect more than 1 in 10 people) include nausea (feeling sick), musculoskeletal pain (bone and muscle pain), neutropenia (low levels of neutrophils, a type of white blood cells that fights infection) and mucositis (inflammation of the body's moist surfaces, most commonly affecting the mouth and throat).
Estonian: Lartruvo kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, lihaseskeleti valu (luu- ja lihasvalu), neutropeenia (neutrofiilide ehk teatud infektsioonivastaste valgeliblede vähesus) ja mukosiit (limaskestapõletik, mis kõige sagedamini esineb suus ja kurgus).
English: Lartruvo is used together with doxorubicin (another cancer medicine) in patients who cannot undergo surgery or radiotherapy (treatment with radiation) and who have not been previously treated with doxorubicin.
Estonian: Lartruvot kasutatakse koos doksorubitsiiniga (samuti vähiravim) patsientidel, keda ei ole võimalik opereerida ega ravida kiiritusraviga ning keda ei ole varem doksorubitsiiniga ravitud.
English: How is Lartruvo used?
Estonian: Kuidas Lartruvot kasutatakse?
English: Lartruvo is a cancer medicine used to treat adults with advanced soft tissue sarcoma, a type of cancer that affects the soft, supportive tissues of the body such as muscles, blood vessels and fat tissue.
Estonian: Lartruvo on vähiravim, mida kasutatakse pehmekudede kaugelearenenud sarkoomiga (keha pehmekudesid, tugikudesid nagu lihased, veresooni ja rasvkude mõjutav pahaloomuline kasvaja) täiskasvanute raviks.
English: The active substance in Lartruvo, olaratumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a protein called ‘platelet-derived growth factor receptor alpha' (PDGFRα).
Estonian: Lartruvo toimeaine olaratumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära valgu, nimelt trombotsüütidest tuletatud kasvufaktori α-retseptori (PDGFRα), ja seondub sellega.
English: What benefits of Lartruvo have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Lartruvo kasulikkus?
English: Lartruvo is available as a solution for infusion (drip) into a vein.
Estonian: Lartruvot turustatakse veeni tilgutatava infusioonilahusena.
English: What measures are being taken to ensure the safe and effective use of Herzuma?
Estonian: Mis meetmed võetakse, et tagada Herzuma ohutu ja efektiivne kasutamine?
English: Patients who tolerate the first 90-minute infusion can receive subsequent infusions over 30 minutes.
Estonian: Patsiendid, kes taluvad esimest 90-minutilist infusiooni, võivad saada järgmised infusioonid 30minutilistena.
English: It is used on its own in patients in whom previous treatments have failed.
Estonian: Ravimit kasutatakse ainuravimina patsientidel, kelle varasem ravi on ebaõnnestunud.
English: The full EPAR for Herzuma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Herzuma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This means that Herzuma is similar to another biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU).
Estonian: See tähendab, et Herzuma sarnaneb bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba.
English: The infusion may be associated with allergic reactions, so the patient should be monitored during and after the infusion.
Estonian: Infusioon võib tekitada allergilisi reaktsioone, mistõttu tuleb patsienti infusiooni ajal ja järel jälgida.
English: What is Herzuma and what is it used for?
Estonian: Mis on Herzuma ja milleks seda kasutatakse?
English: Other information about Herzuma
Estonian: Muu teave Herzuma kohta
English: There were no relevant differences in the main measure of effectiveness (absence of invasive cancer cells in the breast or in linked tissues called lymph nodes) between the two products: this was seen in nearly 44% of those given Herzuma (118 of 271) and 47% of those given Herceptin (131 of 278).
Estonian: Efektiivsuse põhinäitaja (invasiivsete vähirakkude puudumine rinnanäärmes või kaenlalümfisõlmedes) puhul ei täheldatud kahe ravimi vahel olulisi erinevusi - sellise ravivastuse saavutas ligikaudu 44% Herzumat kasutanud patsientidest (118 patsienti 271st) ja 47% Herceptini kasutanud patsientidest (131 patsienti 278st).
English: In addition, one main study involving 549 patients with early breast cancer that overexpressed HER2 showed that Herzuma was as effective as Herceptin.
Estonian: Peale selle tõendati põhiuuringus, milles osales 549 HER2 üleekspressiooniga varases staadiumis rinnavähiga patsienti, et Herzuma oli sama efektiivne kui Herceptin.
English: Why is Herzuma approved?
Estonian: Miks Herzuma heaks kiideti?
English: For early breast cancer, treatment is given for a year or until the disease comes back, and for metastatic breast or gastric cancer, treatment is continued for as long as it remains effective.
Estonian: Varases staadiumis rinnavähi korral manustatakse ravimit üks aasta või kuni haigus taastub ning metastaatilise rinnavähi või maovähi ravi jätkatakse nii kaua, kuni see on efektiivne.
English: The most common or serious side effects with Herzuma are heart problems, reactions related to the Herzuma infusion, reduced levels of blood cells (especially white blood cells), infections and lung problems.
Estonian: Herzuma kõige sagedamad või raskemad kõrvalnähud on südamehäired, Herzuma infusiooniga seotud reaktsioonid, vererakkude, eriti leukotsüütide (vere valgeliblede) sisalduse vähenemine, infektsioonid (nakkused) ja kopsuhäired.
English: Herzuma can cause cardiotoxicity (harm to the heart), including heart failure (when the heart does not work as well as it should).
Estonian: Herzuma võib põhjustada kardiotoksilisust (kahjustada südant), sealhulgas südamepuudulikkust.
English: Herzuma trastuzumab
Estonian: Herzuma trastusumaab
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Herzuma have been included in the summary of product characteristics and the package leaflet.
Estonian: Herzuma ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Herzuma has been shown to have a comparable quality, safety and effectiveness to Herceptin.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt Euroopa Liidu nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Herzuma võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil ravimi Herceptin profiiliga.
English: Therefore, the Agency's view was that, as for Herceptin, the benefit outweighs the identified risk and Herzuma should be given marketing authorisation.
Estonian: Seetõttu on amet arvamusel, et nagu ka Herceptini korral, ületab Herzuma kasulikkus sellega kaasnevad riskid, ja soovitas anda ravimile Herzuma müügiloa.
English: For the full list of all side effects and restrictions with trastuzumab, see the package leaflet.
Estonian: Trastusumaabi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: HER2 is overexpressed in about a quarter of breast cancers and a fifth of gastric cancers.
Estonian: HER2 üleekspressioon esineb rinnavähijuhtudest ligikaudu veerandi ja maovähijuhtudest viiendiku korral.
English: Herzuma can only be obtained with a prescription and treatment should be started by a doctor who has experience in the use of cancer medicines.
Estonian: Herzuma on retseptiravim ja ravi peab alustama vähiravimite kasutamises kogenud arst.
English: It is not intended to provide practical advice on how to use Herzuma.
Estonian: Hindamisaruandes ei anta Herzuma kasutamise praktilisi nõuandeid.
English: What are the risks associated with Herzuma?
Estonian: Mis riskid Herzumaga kaasnevad?